Bildkälla: Stockfoto

Q-linea: A new distribution partner for the UK market - Redeye

Q-linea has signed a new UK distribution partner in Canadian Pro-Lab Diagnostics. Q-linea’s new UK partner has a long history in manufacturing and distributing laboratory equipment related to microbiology and immunodiagnostics. The company is active in infection and bacteria cultivation, and Pro-Lab Diagnostics UK (a subsidiary) has been established in the UK at least since the 90's. Pro-Lab is also active in the US microbiology laboratory market. This is good news, and this progress could indicate that Q-line is considering a more focused approach towards the ongoing European launch following the discontinued Thermo Fisher collaboration. We look forward to the next report from Q-linea (due on the 16th of February) and clarification if Q-linea will progress with a targeted launch for ASTar in Europe, focusing on some key European markets and countries during 2023. The initial positive share price reaction (4-6%) is justified and understandable after a period of substantial uncertainty following the discontinuation of the Thermo Fisher Scientific collaboration.

Q-linea has signed a new UK distribution partner in Canadian Pro-Lab Diagnostics. Q-linea’s new UK partner has a long history in manufacturing and distributing laboratory equipment related to microbiology and immunodiagnostics. The company is active in infection and bacteria cultivation, and Pro-Lab Diagnostics UK (a subsidiary) has been established in the UK at least since the 90's. Pro-Lab is also active in the US microbiology laboratory market. This is good news, and this progress could indicate that Q-line is considering a more focused approach towards the ongoing European launch following the discontinued Thermo Fisher collaboration. We look forward to the next report from Q-linea (due on the 16th of February) and clarification if Q-linea will progress with a targeted launch for ASTar in Europe, focusing on some key European markets and countries during 2023. The initial positive share price reaction (4-6%) is justified and understandable after a period of substantial uncertainty following the discontinuation of the Thermo Fisher Scientific collaboration.
Börsvärldens nyhetsbrev
ANNONSER